Skip to main content
Premium Trial:

Request an Annual Quote

Jubilant Biosys licenses its Kinase ChemBioBase to Astex Technology

NEW YORK, July 8 - Jubilant Biosys of Bangalore, India said today that it has licensed its kinase target database to Astex Technology, of Cambridge, UK.

 

Under the license, Astex will be able to use the database, called the Kinase ChemBioBase, in its structure-based research on lead compounds for drug discovery.

 

The content in this database is what gives Jubilant a competitive edge, according to Sreeni Devidas, vice president of business development and strategy at Jubilant. The database "has all the relevant information that has never been worked on in kinases," he said, including "over 170,000 compounds and 200,000 structure-activity relationships."

 

Jubilant provides bioinformatics and chemoinformatics services.

 

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.